

# Javier de la Rubia

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6393421/publications.pdf>

Version: 2024-02-01

84  
papers

5,714  
citations

136740

32  
h-index

76769

74  
g-index

89  
all docs

89  
docs citations

89  
times ranked

4947  
citing authors

#	ARTICLE	IF	CITATIONS
1	Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. Blood Advances, 2022, 6, 3234-3239.	2.5	18
2	A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma. Blood Cancer Journal, 2022, 12, 68.	2.8	8
3	Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study. Cancers, 2022, 14, 1921.	1.7	1
4	Panel Sequencing for Clinically Oriented Variant Screening and Copy Number Detection in Chronic Lymphocytic Leukemia Patients. Diagnostics, 2022, 12, 953.	1.3	0
5	Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group. Blood Cancer Journal, 2022, 12, 76.	2.8	5
6	Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia. Bone Marrow Transplantation, 2022, 57, 1389-1398.	1.3	10
7	Circulating Tumor Cells for the Staging of Patients With Newly Diagnosed Transplant-Eligible Multiple Myeloma. Journal of Clinical Oncology, 2022, 40, 3151-3161.	0.8	40
8	Immunogenetic characterization of clonal plasma cells in systemic light-chain amyloidosis. Leukemia, 2021, 35, 245-249.	3.3	10
9	Filanesib in combination with pomalidomide and dexamethasone in refractory MM patients: safety and efficacy, and association with alpha 1-acid glycoprotein (AAG) levels. Phase Ib/II Pomdefil clinical trial conducted by the Spanish MM group. British Journal of Haematology, 2021, 192, 522-530.	1.2	8
10	Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood, 2021, 137, 49-60.	0.6	80
11	Treatment of multiple myeloma-related bone disease: recommendations from the Bone Working Group of the International Myeloma Working Group. Lancet Oncology, The, 2021, 22, e119-e130.	5.1	92
12	Treatment patterns and outcomes in real-world transplant-ineligible patients newly diagnosed with multiple myeloma. Annals of Hematology, 2021, 100, 1769-1778.	0.8	9
13	Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis. Blood Advances, 2021, 5, 2137-2141.	2.5	39
14	Redefining outcomes in immune TTP: an international working group consensus report. Blood, 2021, 137, 1855-1861.	0.6	103
15	Lenalidomide and dexamethasone with or without clarithromycin in patients with multiple myeloma ineligible for autologous transplant: a randomized trial. Blood Cancer Journal, 2021, 11, 101.	2.8	14
16	Tumor cells in light-chain amyloidosis and myeloma show distinct transcriptional rewiring of normal plasma cell development. Blood, 2021, 138, 1583-1589.	0.6	11
17	Validation of the International Myeloma Working Group standard response criteria in the PETHEMA/GEM2012MENOS65 study: are these times of change?. Blood, 2021, 138, 1901-1905.	0.6	23
18	Predictive value of 1q21 gain in multiple myeloma is strongly dependent on concurrent cytogenetic abnormalities and first-line treatment. American Journal of Cancer Research, 2021, 11, 4438-4454.	1.4	0

#	ARTICLE	IF	CITATIONS
19	Assessment of Treatment Response By Iife, Next Generation Flow Cytometry and Mass Spectrometry Coupled with Liquid Chromatography in the GEM2012MENOS65 Clinical Trial. <i>Blood</i> , 2021, 138, 544-544.	0.6	7
20	Long-Term Safety and Efficacy of Caplacizumab for Acquired Thrombotic Thrombocytopenic Purpura (aTTP): The Post-HERCULES Study. <i>Blood</i> , 2021, 138, 2080-2080.	0.6	0
21	Severity of Covid-19 Clinical Outcomes and Mortality in Multiple Myeloma Patients over Year 1 of the Pandemic. <i>Blood</i> , 2021, 138, 2719-2719.	0.6	1
22	Efficacy and safety of open-label caplacizumab in patients with exacerbations of acquired thrombotic thrombocytopenic purpura in the HERCULES study. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 479-484.	1.9	45
23	Measurable Residual Disease by Next-Generation Flow Cytometry in Multiple Myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 784-792.	0.8	175
24	Single-agent daratumumab in patients with relapsed and refractory multiple myeloma requiring dialysis: results of a Spanish retrospective, multicentre study. <i>British Journal of Haematology</i> , 2020, 190, e289-e292.	1.2	14
25	Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma. <i>HemaSphere</i> , 2020, 4, e380.	1.2	3
26	Recent Advances in the Treatment of Patients with Multiple Myeloma. <i>Cancers</i> , 2020, 12, 3576.	1.7	22
27	Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2020, 21, 1630-1642.	5.1	237
28	A critical evaluation of caplacizumab for the treatment of acquired thrombotic thrombocytopenic purpura. <i>Expert Review of Hematology</i> , 2020, 13, 1153-1164.	1.0	8
29	Pembrolizumab as Consolidation Strategy in Patients with Multiple Myeloma: Results of the GEM-Pembresid Clinical Trial. <i>Cancers</i> , 2020, 12, 3615.	1.7	7
30	Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. <i>Blood</i> , 2020, 136, 199-209.	0.6	76
31	Updated results from BELLINI, a phase III study of venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed/refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , 2020, 38, 8509-8509.	0.8	22
32	Analysis of treatment efficacy in the GEM-CESAR trial for high-risk smoldering multiple myeloma patients: Comparison between the standard and IMWG MRD criteria and QIP-MS including FLC (QIP-FLC-MS). <i>Journal of Clinical Oncology</i> , 2020, 38, 8512-8512.	0.8	15
33	Clinical Significance and Biomarkers to Predict Unsustained Complete Remission in Transplant-Eligible Multiple Myeloma. <i>Blood</i> , 2020, 136, 5-6.	0.6	0
34	Therapeutic plasma exchange: Review of current indications. <i>Transfusion and Apheresis Science</i> , 2019, 58, 247-253.	0.5	40
35	Role of urine immunofixation in the complete response assessment of MM patients other than light-chain-only disease. <i>Blood</i> , 2019, 133, 2664-2668.	0.6	11
36	Intravenous busulfan plus melphalan versus melphalan alone as conditioning regimen for patients with multiple myeloma. <i>Annals of Hematology</i> , 2019, 98, 2013-2015.	0.8	9

#	ARTICLE	IF	CITATIONS
37	Flow cytometry for fast screening and automated risk assessment in systemic light-chain amyloidosis. <i>Leukemia</i> , 2019, 33, 1256-1267.	3.3	20
38	First Clinical Study of the B-Cell Maturation Antigen (BCMA) 2+1 T Cell Engager (TCE) CC-93269 in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Interim Results of a Phase 1 Multicenter Trial. <i>Blood</i> , 2019, 134, 143-143.	0.6	127
39	Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma (SMM): Carfilzomib, Lenalidomide and Dexamethasone (KRd) As Induction Followed By HDT-ASCT, Consolidation with Krd and Maintenance with Rd. <i>Blood</i> , 2019, 134, 781-781.	0.6	38
40	Qip-Mass Spectrometry in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. <i>Blood</i> , 2019, 134, 581-581.	0.6	14
41	Factors Associated with Mortality in Patients Experiencing First Episodes of Acquired Thrombotic Thrombocytopenic Purpura (aTTP). Results of the Spanish TTP Registry. <i>Blood</i> , 2019, 134, 1082-1082.	0.6	0
42	Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Baseline Disease Severity. <i>Blood</i> , 2019, 134, 2366-2366.	0.6	2
43	Heavy and Light Chain Monitoring in High Risk Smoldering Multiple Myeloma Patients Included in the GEM-CESAR Trial: Comparison with Conventional and Minimal Residual Disease IMWG Response Assessment. <i>Blood</i> , 2019, 134, 1852-1852.	0.6	1
44	Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma. <i>Blood</i> , 2018, 131, 301-310.	0.6	216
45	Pomalidomide Plus Low-Dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and Renal Impairment: Results From a Phase II Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 2035-2043.	0.8	55
46	The safety of daratumumab for the treatment of multiple myeloma. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 753-760.	1.0	6
47	Immunotherapy for the treatment of Hodgkin lymphoma. <i>Expert Review of Hematology</i> , 2017, 10, 417-423.	1.0	12
48	Which therapies will move to the front line for multiple myeloma?. <i>Expert Review of Hematology</i> , 2017, 10, 383-392.	1.0	14
49	Depth of Response in Multiple Myeloma: A Pooled Analysis of Three PETHEMA/GEM Clinical Trials. <i>Journal of Clinical Oncology</i> , 2017, 35, 2900-2910.	0.8	248
50	Infectious complications in patients with newly diagnosed multiple myeloma: A complication from the past?. <i>Leukemia and Lymphoma</i> , 2016, 57, 258-268.	0.6	6
51	Diagnostic and therapeutic guidelines of thrombotic microangiopathies of the Spanish Apheresis Group. <i>Medicina Clínica (English Edition)</i> , 2015, 144, 331.e1-331.e13.	0.1	2
52	Bortezomib-based induction therapy followed by intravenous busulfan+melfalan as conditioning regimen for patients with newly diagnosed multiple myeloma. <i>Leukemia and Lymphoma</i> , 2015, 56, 415-419.	0.6	8
53	Clinical treatment of newly diagnosed multiple myeloma. <i>Expert Review of Hematology</i> , 2015, 8, 595-611.	1.0	13
54	European Perspective on Multiple Myeloma Treatment Strategies in 2014. <i>Oncologist</i> , 2014, 19, 829-844.	1.9	90

#	ARTICLE	IF	CITATIONS
55	Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. <i>New England Journal of Medicine</i> , 2014, 371, 906-917.	13.9	697
56	Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. <i>Lancet Oncology</i> , 2014, 15, 1195-1206.	5.1	695
57	Intravenous Busulfan and Melphalan as a Conditioning Regimen for Autologous Stem Cell Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Matched Comparison to a Melphalan-Only Approach. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 69-74.	2.0	60
58	Analysis of the immune system of multiple myeloma patients achieving long-term disease control by multidimensional flow cytometry. <i>Haematologica</i> , 2013, 98, 79-86.	1.7	132
59	High-risk cytogenetics and persistent minimal residual disease by multiparameter flow cytometry predict unsustained complete response after autologous stem cell transplantation in multiple myeloma. <i>Blood</i> , 2012, 119, 687-691.	0.6	274
60	Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study. <i>Blood</i> , 2012, 120, 1589-1596.	0.6	429
61	Treatment of multiple myeloma in the elderly: realities and hopes. <i>Leukemia and Lymphoma</i> , 2011, 52, 9-14.	0.6	3
62	Bortezomib for previously untreated multiple myeloma. <i>Expert Review of Hematology</i> , 2011, 4, 381-398.	1.0	3
63	Long-term prognostic significance of response in multiple myeloma after stem cell transplantation. <i>Blood</i> , 2011, 118, 529-534.	0.6	183
64	Busulfan 12 mg/kg plus melphalan 140 mg/m <sup>2</sup> versus melphalan 200 mg/m <sup>2</sup> as conditioning regimens for autologous transplantation in newly diagnosed multiple myeloma patients included in the PETHEMA/GEM2000 study. <i>Haematologica</i> , 2010, 95, 1913-1920.	1.7	101
65	Activity and safety of lenalidomide and dexamethasone in patients with multiple myeloma requiring dialysis: a Spanish multicenter retrospective study. <i>European Journal of Haematology</i> , 2010, 85, 363-365.	1.1	34
66	DEPTOR expression and response to thalidomide: toward a new therapeutic target in multiple myeloma?. <i>Leukemia and Lymphoma</i> , 2010, 51, 1960-1961.	0.6	8
67	Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: Results of a Spanish multicenter study. <i>Transfusion and Apheresis Science</i> , 2010, 43, 299-303.	0.5	56
68	Newly diagnosed versus relapsed idiopathic thrombotic thrombocytopenic purpura: a comparison of presenting clinical characteristics and response to treatment. <i>Annals of Hematology</i> , 2009, 88, 973-978.	0.8	15
69	Single daily dose of intravenous busulfan and melphalan as a conditioning regimen for patients with multiple myeloma undergoing autologous stem cell transplantation: a phase II trial. <i>Leukemia and Lymphoma</i> , 2009, 50, 216-222.	0.6	24
70	Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study. <i>British Journal of Haematology</i> , 2008, 143, 39-45.	1.2	57
71	Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation. <i>Blood</i> , 2008, 112, 4017-4023.	0.6	425
72	Follow-up of healthy donors receiving granulocyte colony-stimulating factor for peripheral blood progenitor cell mobilization and collection. Results of the Spanish Donor Registry. <i>Haematologica</i> , 2008, 93, 735-740.	1.7	62

#	ARTICLE	IF	CITATIONS
73	Effect of chemotherapy with alkylating agents on the yield of CD34+ cells in patients with multiple myeloma. Results of the Spanish Myeloma Group (GEM) Study. Haematologica, 2006, 91, 621-7.	1.7	39
74	Pegfilgrastim as adjunct to chemotherapy to mobilize hematopoietic stem cells. Haematologica, 2005, 90, 150.	1.7	5
75	Second Mobilization and Collection of Peripheral Blood Progenitor Cells in Healthy Donors Is Associated with Lower CD34+Cell Yields. Journal of Hematotherapy and Stem Cell Research, 2002, 11, 705-709.	1.8	16
76	Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors. Transfusion, 2002, 42, 4-9.	0.8	87
77	SÃndrome HELLP. Medicina ClÃnica, 2001, 117, 64-68.	0.3	7
78	Development of non-ABO RBC alloantibodies in patients undergoing allogeneic HPC transplantation. Is ABO incompatibility a predisposing factor?. Transfusion, 2001, 41, 106-110.	0.8	37
79	Donor age-related differences in PBPC mobilization with rHuG-CSF. Transfusion, 2001, 41, 201-205.	0.8	50
80	Conditioning regimens in autologous stem cell transplantation for multiple myeloma: a comparative study of efficacy and toxicity from the Spanish Registry for Transplantation in Multiple Myeloma. British Journal of Haematology, 2000, 109, 138-147.	1.2	69
81	Mild hemolytic disease of the newborn due to anti-Goa. Transfusion, 1999, 39, 537-537.	0.8	2
82	Autologous peripheral blood stem cell transplantation for acute leukaemias. Best Practice and Research in Clinical Haematology, 1999, 12, 139-150.	0.7	7
83	SEVERE HEMOLYTIC ANEMIA DUE TO ANTI-E AFTER RENAL TRANSPLANTATION. Transplantation, 1997, 64, 550,551.	0.5	12
84	Anaphylactic Shock and Vitamin K_1. Annals of Internal Medicine, 1989, 110, 943.	2.0	46